- Home
- AGEN vs NMT Comparison
AGEN vs NMT Comparison
Compare AGEN & NMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGEN | NMT |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 107.8M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGEN | NMT |
|---|---|---|
| Price | $3.16 | $11.88 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 372.3K | 19.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $42,877,086.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $68.25 | N/A |
| P/E Ratio | $8.04 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $1.38 | $10.90 |
| 52 Week High | $7.34 | $12.33 |
Technical Indicators
Market Signals| Indicator | AGEN | NMT |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 65.36 |
| Support Level | $2.90 | $11.47 |
| Resistance Level | $3.38 | $12.20 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 52.69 | 54.05 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.